Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic characterization of brain metastases reveals branched evolution and metastasis-specific mutations
    Meeting Abstract

    Brastianos, P.; Carter, S.; Santagata, S.; Taylor-Weiner, A.; Jones, R.; Van Allen, E.; Horowitz, P.; Ligon, K.; Cahill, D.; Dunn, I.; more...
    Neuro-Oncology (2014)

    Fulltext@MSK | Save
  • Novel regulation of estrogen receptor transcription by the PI3K pathway
    Meeting Abstract

    Toska, E.; Elkabets, M.; Bosch, A.; Litvin, O.; Scaltriti, M.; Baselga, J.
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer
    Meeting Abstract

    Carmona Sanz, F.; Montemurro, F.; Rossi, V.; Verma, C.; Berger, M.; Baselga, J.; Scaltriti, M.
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Disease-free survival (DFS) in the lapatinib alone arm and expanded results of the phase III ALTTO trial (BIG 2-06; NCCTG (alliance) N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC)
    Meeting Abstract

    Perez, E. A.; Holmes, E.; de Azambuja, E.; Dueck, A.; Baselga, J.; Viale, G.; Zujewski, J. A.; Goldhirsch, A.; Crescenzo, R.; Pritchard, K.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs)
    Meeting Abstract

    Johnson, S.; Johnson, N.; Chi, D.; Primack, B.; Cruz, C.; Stover, D.; Greifenberg, A. K.; Cao, S.; O'connor, K.; Baselga, J.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Development of xenoimplants from germline BRCA1/2 mutant breast cancer (BC) for the identification of predictive biomarkers, mechanisms of resistance against poly(ADP-ribose) polymerase (PARP) inhibitors and evaluation of novel therapies
    Meeting Abstract

    Cruz, C.; Ibrahim, Y.; Morancho, B.; Antón, P.; Grueso, J.; Cozar, P.; Guzman, M.; Aviles, P. M.; Guillen, M. J.; Galmarini, C.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: A case of convergent evolution under selective therapeutic pressure
    Meeting Abstract

    Castel, P.; Juric, D.; Griffith, M.; Griffith, O. L.; Won, H. H.; Ainscough, B.; Ellis, H.; Ebbesen, S.; Gopakumar, I.; Quadt, C.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (resilience)
    Meeting Abstract

    Baselga, J.; Zamagni, C.; Gomez, P.; Bermejo, B.; Nagai, S.; Melichar, B.; Chan, A.; Mangel, L.; Bergh, J.; Costa, F. P.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    Journal Article

    Piccart, M.; Hortobagyi, G. N.; Campone, M.; Pritchard, K. I.; Lebrun, F.; Ito, Y.; Noguchi, S.; Perez, A.; Rugo, H. S.; Deleu, I.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer
    Journal Article

    Saura, C.; Garcia-Saenz, J. A.; Xu, B.; Harb, W.; Moroose, R.; Pluard, T.; Cortés, J.; Kiger, C.; Germa, C.; Wang, K.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save